Xenetic Bio Share Discussion Threads

[ashthorpedo] 02/2/2016 17:02

I would have thought that the company would have given some details of listing by now. Can't see it happening by 31 March. They have to give a quarterly statement by the middle of this month so perhaps we'll be given an update then.

[mr_brightside] 21/1/2016 20:08

Hey up, anyone around. Need to get this board going again!! Anyone know yet why we shot up to $1.09 a while back? Couldn't find anything...

[buywell2] 17/1/2016 22:45

Regarding the above


This shows that the area that needs to be improved by the authorities is Pre Clinical trials


The FDA and EMA do not stipulate the use of human living cells from the liver, brain, heart, kidneys and other organs to be used in BOTH in silico AND in vitro Toxicology assays.


It is absolutely disgusting that in 2016 humans become the guinea pigs and as a result die

Politicians need to be held to account










France drug trial: Brain-dead man dies in hospital



A man left brain-dead after an experimental drug trial in France has died, local media report.

He was one of six people being treated in hospital in the city of Rennes.

The hospital said the other five remained in a stable condition - four had "neurological problems" and the fifth had no symptoms.

Reports that the drug was a cannabis-based painkiller have been denied by the French health ministry. The Paris prosecutor has opened an investigation

The trial, which involved taking the drug orally and has now been suspended, was conducted by a private laboratory in Rennes.

Ninety volunteers took the drug, manufactured by the Portuguese company Bial.

Ten of the other 84 have been tested, but did not display any of the "anomalies" of those admitted, the Rennes hospital said in its statement (in French).

On Friday, the chief neuroscientist at the hospital, Gilles Edan, said there was no known antidote to the drug.

Analysis: James Gallagher, health editor, BBC News website

This is the bitter price of the new medicines we take for granted. Testing such experimental drugs, at the cutting edge of science, can never be completely risk-free.

The safety and effectiveness of these drugs are rigorously tested in animals. The risks are low but there must still be a leap of faith when they are tried in people for the first time.

This trial has been taking place since July without such major events being reported. Generally in Phase I trials the dose is increased slowly over time, which could be why the side-effects are appearing now.

The hospitalised men started taking the drug regularly on 7 January and began showing severe side-effects three days later.

It is a high price to pay, but thousands of people do safely take part in similar trials each year.

The trial was conducted by Biotrial, a French-based company with an international reputation which has carried out thousands of trials since it was set up in 1989.

The study was a Phase I clinical trial, in which healthy volunteers take the medication to evaluate the safety of its use, the ministry said.

Before any new medicine can be given to patients, detailed information about how it works and how safe it is must be collected.

Clinical trials are the key to getting that data - and without volunteers to take part in the trials, there would be no new treatments for serious diseases such as cancer, multiple sclerosis and arthritis.

New EU regulations to speed up clinical drug trials and streamline testing procedures across the 28-nation bloc are due to take effect in 2018.
Clinical trials

Trials typically have three phases to assess a new medicine for safety and effectiveness


Phase I tests for safety. A small number of people, sometimes healthy, and sometimes with a medical condition, are given a tiny dose of the drug under careful supervision, not to test if the drug works, but in order to check for any side effects

Phase II sees the drug given to people who have a medical condition to see if it does indeed help them

Phase III trials are only for medicines or devices that have already passed the first two stages, and involve them being compared to existing treatments or a placebo. The trials often last a year or more, involving several thousand patients

[buywell2] 09/12/2015 22:27

‘Post-antibiotic era’ looms amid unregulated drugs market – UK govt review
20 Nov, 2015 15:04

Unregulated antibiotic sales in pharmacies and online are fueling the rise of deadly “superbug̶1; bacteria as the world sits on the cusp of an “antibiotic apocalypse,” according to a UK government-commissioned report.

Antibiotics can only be obtained by a doctor’s prescription in the UK, but it is relatively commonplace in many low- and middle-income countries for the drugs to be bought over the counter.

The report published on Friday urges governments, regulators and online firms to clamp down on unlicensed sales of antibiotics.

It comes amid global alarm about the discovery in China of a gene that makes bacteria resistant to even the strongest available antibiotic, prompting some scientists to warn the world is on the cusp of a ‘post-antibiotic era.’

In the government-commissioned report, former Goldman Sachs chief economist Jim O’Neill said the global threat is exacerbated by patients self-medicating with drugs from online pharmacies.

“Even in those countries where it’s next to impossible to buy antibiotics over-the-counter in a shop, it’s still often the case that an unscrupulous online pharmacy is just a few clicks away,” he said in a statement.

“These internet drug stores could be based anywhere in the world, so it’s vital that regulators – along with the industry, customs organizations and internet companies – work together to crack down.”

O’Neill said over-the-counter sales of antibiotics “remains relatively commonplace in Southern and Eastern Europe and many low- and middle-income countries.”

Overmedication and misuse of antibiotics is a major contributor to the evolution of bacteria resistance.

It is thought the overuse of colistin – the drug of last resort – in farm animals led to the creation of the world’s first completely antibiotic-resistant bacteria which was discovered in China.

The new mutation, dubbed the MCR-1 gene, may have already spread to Laos and Malaysia.

Professor Timothy Walsh of the University of Cardiff’s Institute of Infection & Immunity told the BBC the world is on the cusp of the “post-antibiotic era.”

“All the key players are now in place to make the post-antibiotic world a reality,” he said.

“If MCR-1 becomes global, which is a case of when not if, and the gene aligns itself with other antibiotic resistance genes, which is inevitable, then we will have very likely reached the start of the post-antibiotic era.

“At that point if a patient is seriously ill, say with E. coli, then there is virtually nothing you can do,” he added.

[corrientes] 07/12/2015 21:18

1.15m shares traded today. Highest volume for a long time I think.

[buywell3] 25/11/2015 22:23

USA OTC market does that

[jammytass] 25/11/2015 18:56

price rise very fast

[digger18] 20/11/2015 13:45

I refer to Maguire the magician or squanderer. We now need solid news before further fund raising.

[ashthorpedo] 18/11/2015 14:56

At todays price 51c, 1 for 10 is $5.10. But just in case the price falls further the RNS states at least 1 for 10 so if it falls to 20c then we'll just have a 1 for 20. Abracadabra $4!
No magician needed just a basic calculator.

[digger18] 18/11/2015 13:00

I don't think 1:10 consolidation to net at $1.50 meets the NASDAQ qualification requirements. $4 closer to the mark. We will see if the magician can pull it off.

[ashthorpedo] 18/11/2015 12:54

Its no wonder Maguire was looking for the authorised share capital to be increased to 1.5 billion shares, he's been handing them out like confetti.
Deals with Pharmsynthez
3 July 2015 3 Million Bridge note entitled to convert loan at 15c per share thats 20 million shares also entitled to buy a further 10 million at 20c beginning 01 January 2016.
13 Nov 2015 100.5 Million shares for Virexxa, 11 million shares for the inventors, 3.5 million loans convertible at 15c 23 1/3 million shares and warrants of 11 2/3 million at 20c, management get warrants to purchase 5 million shares at 42c, and finally Pharmsynthez entitled to purchase £6.5 million shares in capital raise at a price to be agreed yet.
Yes Buywell3 the shares will float in excess of $1.50 but don't get excited only after the 1 for 10 share consolidation.

[dutchgold77] 14/11/2015 20:21

Easiest money you will make.
How many small pharmas have a massive backing of
1. The Russian government as no 1 shareholder and basing their pharma off their technology
2. Baxalta using polyxen for factor viii and maybe more and shareholder
3. Serum institute of India- worlds biggest vaccine maker and shareholder

These guys are no time wasters

[buywell3] 12/11/2015 23:56

If Baxter thought XEN technology worthy of investing their Factor V111 future on

Plus the Russian Government putting the future of quite a proportion of their own biotech expansion plans

Plus the largest vaccine manufacturer in India also paying for and carrying out clinical trials on a drug which will soon be used across India

Then one would imagine USA investors will be wanting in when XEN lists in NASDAQ on the back of further positive clinical trials news plus NEW Orphan drug developments which should ONLY benefit XEN shareholders

I would imagine the float price will be in excess of 1.5$


Wonder if the knockers/prats agree ?

[jammytass] 11/11/2015 16:41

On the rise again

[corrientes] 11/11/2015 15:10

Volume is consistently high for last few days, on a historical basis anyway.

Maybe its been tipped by some small broker. Judging by the past few months, this one is prone to great volatility. Anyone know what the free float is ?

[trotterstrading] 11/11/2015 14:29

I had a look, nothing immediately obvious.

Being on the OTC market means we are prone to huge swings in the share price on small volume so I'm not reading to much into the rise, that said the trend is definitely up and we have Nasdaq uplift to look forward to before June 2016

[mr_brightside] 11/11/2015 13:57

Lift off! Great stuff... anyone know why though? Been looking around for news about why this has surged 78% but can't find anything!

[smcl] 10/11/2015 20:32

Excellent!

[jammytass] 10/11/2015 20:02

Boom watch this go on the us markets. Major rise

[trotterstrading] 19/10/2015 14:58

At least we have a recorded date for Nasdaq to track against now

[corrientes] 08/10/2015 12:44

That's if all markets haven't crashed by then. Seems like the jam tomorrow is spreading thinner and thinner.

[trotterstrading] 07/10/2015 17:33

Big news today:



NASDAAQ Uplift not far off now, my guess is before Xmas

[buywell3] 17/9/2015 08:14

I will be very surprised if the NASDAQ float does not take place before this xmas

The delay as I understand it is due to some very positive data coming through which will make Xenetic even more attractive to USA investors who want in.

This data will need to be included in the prospectus and will make Xenetic an even more compelling investment.

The Market Cap of this should exceed $300M on NASDAQ

Recent sellers will be somewhat miffed ... is my prediction

dyor